Menu Search
Equities

Arvinas Inc

ARVN:NSQ

Arvinas Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)27.14
  • Today's Change-0.61 / -2.20%
  • Shares traded840.21k
  • 1 Year change+64.39%
  • Beta1.8385
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Arvinas Inc's revenues fell -40.26% from 131.40m to 78.50m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 282.50m to a larger loss of 367.30m.
Gross margin--
Net profit margin-191.56%
Operating margin-221.85%
Return on assets-27.73%
Return on equity-59.16%
Return on investment-37.81%
More ▼

Cash flow in USDView more

In 2023, Arvinas Inc increased its cash reserves by 265.44%, or 230.40m. Cash Flow from Financing totalled 374.70m or 477.32% of revenues. In addition the company used 347.80m for operations while cash from investing totalled 203.50m.
Cash flow per share-4.48
Price/Cash flow per share--
Book value per share8.53
Tangible book value per share8.53
More ▼

Balance sheet in USDView more

Arvinas Inc uses little debt in its capital structure as supported by a debt to capital ratio of 0.10%.
Current ratio4.17
Quick ratio--
Total debt/total equity0.001
Total debt/total capital0.001
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.